This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Neurology  • Substance Abuse/ Alcoholism  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

We read with great interest the recent meta-analysis by Mayo-Smith et al¹ about the management of alcohol withdrawal delirium (AWD). The authors included new clinical data on the management of AWD, ranging from a single case report to a prospective randomized trial from 1966 to 2001. Since the time considered, among the possible new drugs useful in the management of AWD, the authors did not mention the possible utility of the -aminobutyric acid (GABA receptor agonist baclofen. Baclofen is able to suppress alcohol withdrawal symptoms both in animals² and in humans³ and may be effective in reducing voluntary alcohol intake in alcohol-preferring rats² and alcohol craving and intake in alcoholic individuals.⁴ We recently described a patient in whom AWD was rapidly and completely suppressed by baclofen administration.⁵ We believe that prior clinical data suggest that baclofen could be a useful new drug in the treatment of AWD, although future controlled . . . [Full Text of this Article]

AUTHOR INFORMATION
Lorenzo Leggio, MD; Ludovico Abenavoli, MD; Fabio Caputo, MD; Giovanni Gasbarrini, MD; Giovanni Addolorato, MD